Resmed Inc (RMD)
被低估基本面
75
价格
$221.10
市值
$32.04B
第一部分 · 这家公司值多少
概览
ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
资产负债表与流动性
营收
$5.65B
最近12个月(截至2026/6/30)
净利润
$1.52B
最近12个月(截至2026/6/30)
自由现金流
$1.65B
股东权益合计
$6.59B
负债合计
$2.38B
流动比率
3.10
利息覆盖率
-
债务/EBITDA
0.40
每股收益
营收与净利润
自由现金流
收入构成
历史财务表
利润率变化
债务变化
债务负担有多重
增长一览表
增长 — 营业收入
公允价值估算
公允价值
$347.45
当前价格
$221.10
安全边际
+36.4%
公允价值区间
$225.84 - $469.06
所用估值方法之间的离散区间,并非经过统计校准的置信区间。
估算方法
估值指标
市盈率(P/E)
21.20
ROE
23.1%
市净率(P/B)
4.84
P/FCF
19.34
毛利率
61.1%
ROIC
19.7%
盈利能力雷达图
价值创造(经济护城河)
ROIC
19.7%
WACC
8.5%
ROIC − WACC
+11.2 pp
ROIC 超过资本成本:公司正在为股东创造价值。
基本面分析标准
通过(19)
- EPS shows upward trend
- EPS CAGR 15.14%
- Price CAGR 13.41%
- ROIC 19.7%
- Gross Margin 61.1%
- P/FCF 19.34
- Debt/Equity ratio
- Operating Margin 33.4%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- ROE 23.9%
- Revenue Growth 5Y 12.1%
- PEG Ratio 0.79
- Earnings Quality (OCF/NI) 1.19
- Share Dilution -0.8%
- Piotroski F-Score 7/9
未通过(7)
- P/B Ratio 4.84
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Analyst Consensus 48% Buy
- Earnings Surprise avg 0.8%
- Net Margin Trend 26.9% vs 27.2%
不可用(2)
- Dividend Payout NaN%
- Interest Coverage
Piotroski F-评分
财务状况强健
盈利质量
高质量:盈利有现金流支撑
股权稀释
正在回购股份,对股东友好
机构持股
公司治理
管理团队
| 姓名 | 职位 | 年龄 |
|---|---|---|
| Mr. Michael J. Farrell BE, MBA, SM | CEO & Chairman | 53 |
| Dr. Peter C. Farrell A.M., B.E., BE (Hons), Ph.D., ScD | Founder, Chair Emeritus & Non-Executive Director | 83 |
| Mr. Michael J. Rider | Chief Legal Officer & Secretary | 67 |
| Mr. Brett A. Sandercock | Advisor | 58 |
| Mr. Justin Leong | Chief Product Officer | 47 |
| Mr. Aaron Bloomer | Chief Financial Officer | 39 |
| Mr. Alastair Robertson | Chief Information Officer | - |
| Ms. Sallilyn Schwartz | Chief Investor Relations Officer | - |
| Mr. Jim Ellis | Chief Compliance Officer | - |
| Ms. Yvonne-Katrin Pucknat | Chief Marketing Officer | 49 |
审计风险
1
董事会风险
7
薪酬风险
4
股东权利风险
3
第二部分 · 价格与买入时机
这一部分不判断公司是否值得拥有:它帮助你在基本面说服你之后,选择何时买入。包含:技术分析、潜力、历史回撤、Gamma 敞口。
损益历史
via SEC EDGAR
Latest News
Recent headlines for RMD, sourced from Markets Gazette.
- 3/10/2026POSITIVE3 Reasons Not to Sleep on ResMed Stock
ResMed Inc., a prominent player in the sleep apnea and respiratory care market, is highlighted for its leadership in CPAP machines and other vital medical devices. The company's focus on improving respiratory health for millions globally positions it favorably within the healthcare sector. Investors are advised not to overlook ResMed's potential, suggesting a positive outlook driven by its established market position and ongoing innovation in medical technology. The company's products address a significant and growing health concern, underpinning its long-term value proposition.
- 3/4/2026POSITIVEHere's How Much You Would Have Made Owning ResMed Stock In The Last 10 Years
ResMed Inc. (RMD) stock has delivered exceptional performance over the past 10 years, offering investors significant returns. While the article doesn't provide exact figures, the title "Here's How Much You Would Have Made" implies consistent and profitable growth. This is crucial for investors assessing the long-term potential of the medical device and sleep-care solutions sector. Past performance, while not guaranteeing future results, indicates ResMed's strong ability to generate shareholder value, potentially driven by product innovation, market expansion, and sound management.
via Markets Gazette